ICON Plc

ICON Plc ICON is a global provider of outsourced clinical research development services to the pharmaceutical, biotechnology, and medical device industries.

We help our clients accelerate the development of life-saving drugs that improve patients' quality of life.

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinica...
20/02/2026

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development.

This article in Select Science explores the evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and ex*****on. https://ow.ly/uAQW50YhqXJ

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistic...
19/02/2026

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/JE8X50YgoXv

The EU Joint Clinical Assessment ( ), launched in 2025, is reshaping how oncology and trials are designed and assessed...
19/02/2026

The EU Joint Clinical Assessment ( ), launched in 2025, is reshaping how oncology and trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing one clinical value assessment, sponsors must plan earlier, justify comparators more rigorously and integrate patient‑focused endpoints from the start.

Dr. Liz O’Brien, ICON, outlines how JCA is changing global protocol strategy, strengthening engagement with patient groups and accelerating access to innovative therapies by reducing duplication across markets.

Read more here: https://ow.ly/rnCM50Yf25z

New analyses show that well-implemented DHTs can:- Reduce trial timelines by 3–5 months- Decrease enrollment requirement...
19/02/2026

New analyses show that well-implemented DHTs can:
- Reduce trial timelines by 3–5 months
- Decrease enrollment requirements by up to 16%
- Lower protocol amendment risk
- Deliver meaningful ROI in both Phase II and Phase III programs

But to realize these benefits, sponsors must navigate data governance, site readiness, patient onboarding, and a crowded vendor ecosystem.

Our recent article in BiopharmaTrend.com breaks down where DHTs can deliver real financial and operational impact, and what it takes to get there.

Read more: https://ow.ly/5tzH50Y9MJ1

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted b...
18/02/2026

Join us to explore the latest best practices in global flow cytometry QC and harmonisation.

During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss:
- Industry best practices for harmonisation of flow cytometry data
- Where bench-side quality control testing fits into larger quality management structures
- ‘Total Error Allowable’ and ‘Statistical Process Controls’ as applied to real-time quality control monitoring of flow cytometry assay performance.

Register here: https://ow.ly/gNwN50Yf2g7

How do patient-led organisations help bring therapies to families faster? Our live webinar gathers relentless leaders to...
18/02/2026

How do patient-led organisations help bring therapies to families faster? Our live webinar gathers relentless leaders to explore real world examples of patient-led innovation reshaping drug development and regulatory strategy in ultra rare diseases.

Save your spot for 3 March: https://ow.ly/6E3750Y8ER7

ADCs are transforming cancer treatment by combining targeted monoclonal antibodies with powerful cytotoxic agents. Howev...
17/02/2026

ADCs are transforming cancer treatment by combining targeted monoclonal antibodies with powerful cytotoxic agents. However their complexity poses bioanalytical challenges.

Scientists face major challenges due to ADC heterogeneity, variable drug-to-antibody ratios, and the need for precise pharmacokinetic (PK) and immunogenicity assessments. Advanced techniques like LC–MS/MS and ligand-binding assays are essential to tackle these obstacles.
In this Bioanalysis Zone spotlight ICON experts share insights, challenges and solutions in ADC bioanalytics.

Read on to learn more: https://ow.ly/3igA50YbCob

Symphony Health, an ICON plc company, is delivering stronger, deeper oncology insights than ever before. Our enhanced on...
16/02/2026

Symphony Health, an ICON plc company, is delivering stronger, deeper oncology insights than ever before. Our enhanced oncology data captures more patients, more claims, and more treating HCPs, giving life sciences teams clearer visibility across the entire oncology journey.

These expanded insights help improve forecasting, targeting, access pathways, and understanding of real world treatment behaviours across major cancer types.

Want to know what this uplift looks like for your specific oncology market and how it could strengthen your strategy? Connect with us today. https://ow.ly/K8Yi50Yc6MZ

Understanding how clinical trials are delivered starts with clarity on the roles that shape them. Our latest blog explai...
16/02/2026

Understanding how clinical trials are delivered starts with clarity on the roles that shape them.

Our latest blog explains how sponsors set the research agenda and retain oversight, how CROs manage operational delivery at scale, and how clinical sites translate protocol into patient-facing research activity. This overview provides practical insight for professionals exploring clinical research careers and those seeking to deepen their industry knowledge.

Read the full article here: https://ow.ly/Wmju50YgysR

Mechanism over indication? EMA’s upcoming MoA PIP requirement signals a major regulatory shift. Read lessons learned fro...
15/02/2026

Mechanism over indication? EMA’s upcoming MoA PIP requirement signals a major regulatory shift.

Read lessons learned from the US’s RACE Act and how the MoA requirements could impact your drug development strategy: https://ow.ly/pf8B50XSUET

ICON is committed to bringing safe, effective, pediatric-tested treatments to children. In the past 5 years, we have par...
15/02/2026

ICON is committed to bringing safe, effective, pediatric-tested treatments to children. In the past 5 years, we have participated in 423 clinical studies, including 22 malignant haematology and 18 oncology/solid tumour studies involving pediatric patients. https://ow.ly/SkLj50Y8BR8

As digital endpoints gain regulatory traction, sponsors who invest in endpoint strategy and validation today will be bet...
13/02/2026

As digital endpoints gain regulatory traction, sponsors who invest in endpoint strategy and validation today will be better positioned to run faster, more inclusive trials tomorrow.
Digital health technologies are enabling continuous, real-world measurement of how patients feel and function, offering richer insights than episodic clinic visits alone.

Read on to learn how sponsors are seeing ROI gains of 5–20x when integrating DHTs. https://ow.ly/U6FH50Y9MHa

Address

South County Business Park, Leopardstown
Dublin
18

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+35312912000

Website

Alerts

Be the first to know and let us send you an email when ICON Plc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ICON Plc:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category